Svien Senne, DO
Pulmonary Disease · Watertown, SDNPI 1467715797
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 50.6% of the total. Reporting peaked in 2024 at $7,590 and has fallen 79.0% since, to $1,591 in 2025. Among pulmonary disease clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Mylan Specialty L.p.$1K
- GSK$1K
- AstraZeneca$923
- Takeda Pharmaceuticals U.S.A., Inc.$774
- Viatris Specialty LLC$433
- plus $2K from 19 others
What the payments were for
- Consulting fees$170%
- Travel & lodging$8717%
- Food & beverage$6,32949%
- Education$5,62244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $6,502 |
| Mylan Specialty L.p. | 85 | $1,359 |
| GSK | 99 | $1,124 |
| AstraZeneca | 53 | $923 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $774 |
| Viatris Specialty LLC | 21 | $433 |
| Grifols USA, LLC | 17 | $275 |
| Insmed, Inc. | 18 | $246 |
| Boehringer Ingelheim | 10 | $209 |
| Verona Pharma, Inc. | 7 | $173 |
| Sanofi | 8 | $163 |
| Baxter Healthcare | 10 | $162 |
| Actelion Pharmaceuticals US, Inc. | 2 | $111 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Johnson & Johnson | 3 | $58 |
| Advanced Respiratory, Inc | 2 | $42 |
| Bayer | 3 | $42 |
| Itamar Medical Inc | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| Sanofi US Services Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Apria Healthcare LLC | 1 | $14 |
| Resmed Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,333
How this compares
$12,840 in reported general payments places this provider in the 90th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,039 | $734,259 |
| OpsumitMacitentan | 37 | $458,926 |
| OfevNintedanib Esylate | 15 | $196,164 |
| Dupixent PenDupilumab | 38 | $156,085 |
| NucalaMepolizumab | 23 | $98,316 |
| TezspireTezepelumab-Ekko | 12 | $57,585 |
| Pirfenidone | 16 | $56,960 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $47,486 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $27,875 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $26,666 |
| Spiriva RespimatTiotropium Bromide | 41 | $22,327 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $15,666 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $14,217 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 71 | $13,968 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 131 | $12,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,124 | $903,9111,249 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $111 | $458,92637 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $209 | $257,452114 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Airsupra, Bevespi Aerosphere | $923 | $109,564136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Watertown
- Scott HelbergYankton$621K
- Michael PietilaYankton$79K
- Lori HansenYankton$10K
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Cliff JanikowskiRapid City$6K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Deptmer AshleyAberdeen$5K
- Kaitlin BranickSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.